Genentech will start a second Phase 3 clinical trial of crenezumab, an anti-Amyloid-beta antibody for treating Alzheimer’s disease that was developed by its partner, AC Immune. This trial, CREAD2, will complement the current randomized, double-blind, placebo-controlled, parallel group Phase 3 clinical trial (CREAD1, NCT02670083). CREAD1 is evaluating the effectiveness and…
Neurotrope has finished dosing and monitoring patients in a Phase 2 clinical trial to evaluate Bryostatin-1, the company’s lead drug candidate for treatment of moderate to severe Alzheimer’s disease. The randomized, double-blind, placebo-controlled, Phase 2 clinical trial (NCT02431468) is assessing the safety, tolerability and efficacy of bryostatin-1 in 148 people…
Sleeping for more than nine hours each night may predict the risk of developing dementia, and people who sleep a lot tend to have smaller brains. Those are among the findings in a new study, “Prolonged sleep duration as a marker of early neurodegeneration predicting incident dementia,” that appeared recently in the…
A brain imaging technique called single photon emission computed tomography, or SPECT, can help clinicians differentiate between depression and a cognitive disorder such as Alzheimer’s disease, according to new research. The study, “ Classification of Depression, Cognitive Disorders, and Co-Morbid Depression and Cognitive Disorders with Perfusion SPECT Neuroimaging,” was published in…
A decade-long study evaluating the impact of a brain training exercise on dementia, often associated with Alzheimer’s disease, was selected to be part of Time magazine’s 100 New Scientific Discoveries of 2016. The National Institutes of Health (NIH)-funded ACTIVE study led to the development of an exercise that was…
Speaking more than one language appears to help the brain resist the effects of Alzheimer’s disease (AD), according to a study by Italy’s Vita-Salute San Rafffaele University in Milan. The study, “The impact of bilingualism on brain reserve and metabolic connectivity in Alzheimer’s dementia,” appeared in the journal Proceedings of the…
The Alzheimer’s Association – New York City Chapter will collaborate with the Delta Rho Omega chapter of Alpha Kappa Alpha Sorority in February to raise awareness about Alzheimer’s disease during Black History Month. The collaboration aims to highlight the prevalence of Alzheimer’s in the African-American community, and involves campus officials…
Neuronascent has been issued a U.S. patent for methods of stimulating neurogenesis and/or inhibiting neuronal degeneration that have potential therapeutic applications in Alzheimer’s disease, Parkinson’s disease, post-traumatic stress disorder, depression, and other psychiatric disorders. The biopharma Neuronascent discovers and develops novel therapeutics aimed at halting or reversing neurological disorders. The…
Researchers at Georgetown University Medical Center (GUMC) are recruiting participants for a clinical trial to evaluate the cancer drug Tasigna (nilotinib) in people with mild to moderate Alzheimer’s disease (AD). The randomized, double-blind, placebo-controlled Phase 2 clinical trial (NCT02947893) will evaluate how low doses of Tasigna impact safety, biomarkers, and…
Meditating or listening to music may benefit adults with preclinical memory loss, including those at risk for Alzheimer’s disease (AD), a new study found. A West Virginia University research team, led by Kim Innes, PhD, conducted a randomized, controlled clinical trial in 60 adults with subjective cognitive decline (SCD),…
Get regular updates to your inbox.